Lattice Biologics Profit Margin

Lattice Biologics (LBLTF) currently reports a profit margin of -59.23% as of June 2021. That compares with -87.27% in the prior-year period — up 32.1% year over year. That is below the sector sector average of 13.2%. Use the charts on this page to explore Lattice Biologics's profit margin history and peer comparisons.

Lattice Biologics's profit margin increased from -87.27% to -59.23% — a 32.1% year-over-year increase (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lattice Biologics's profit margin of -59.23% is lower than the its sector sector average of 13.2%. That is roughly 548.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Lattice Biologics's current -59.23% should be judged against industry norms (sector average: 13.2%) and against LBLTF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -59.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.2%. From there, open related valuation or income-statement pages for Lattice Biologics, and consider following LBLTF for alerts when major investors trade the stock.